7 October 2024 India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative.
Following a regulatory update, Japanese speciality pharma company Kyowa Kirin has announced it will pull the plug on its small molecule bardoxolone methyl. 12 May 2023
The US Food and Drug Administration (FDA) yesterday announced it is requiring sponsors of amphetamine and methylphenidate products, a class of stimulant medications used to treat attention deficit/hyperactivity disorder (ADHD) and other disorders, to update and standardize their prescribing information to clearly inform patients, caregivers and health care professionals of risks associated with their medications. 12 May 2023
The Russian government will consider the allocation up to 48 billion roubles ($625 million) in public procurements of anti-HIV drugs this year, The Pharma Letter’s local correspondent reports. 12 May 2023
French pharma major Sanofi edged up 1% on release of new data that adds to the body of evidence demonstrating nirsevimab’s protection against respiratory syncytial virus (RSV)-related lower respiratory tract disease (LRTD) and confirm its favorable safety profile in multi-country, real-world conditions 12 May 2023
The Indian vaccine market has carved a niche for itself at the global level and is anticipated to reach a valuation of $3.07 billion by 2025, according to Minister of State for Science and Technology Jitendra Singh, who was on an official visit to the UK. 12 May 2023
Privately-held Italian firm Angelini Pharma and Japan’s JCR Pharmaceuticals have agreed an exclusive global development and commercialization agreement for the development of biologics for epilepsy. 11 May 2023
Shares of Denmark’s Zealand Pharma were up more than 10% at 243.00 kroner today after, along with German partner Boehringer Ingelheim, it announced that patients treated with BI 456906 achieved up to 14.9% weight loss after 46 weeks, using the planned maintenance dose. 11 May 2023
German life sciences company Bayer was trading 7% lower in mid-afternoon trading on Thursday after presenting its first-quarter financial results and latest outlook for 2023 as a whole. 11 May 2023
Germany’s Merck KGaA took in 5.3 billion euros ($5.8 billion) in the first quarter, a little short of many analysts’ expectations, a 1.8% increase from the same period of 2022. 11 May 2023
Global drugmakers are in no hurry to leave the Russian market, still considering the local market as one of the most promising for their growth, according to recent statements made by Mikhail Murashko, head of the Russian Ministry of Health. 11 May 2023
Following a positive vote last month from the Joint Meeting of the Psychopharmacologic Drugs Advisory Committee, the US Food and Drug Administration (FDA) has now approved the supplemental New Drug Application (sNDA) of Rexulti (brexpiprazole) for use in the treatment of agitation associated with dementia due to Alzheimer’s disease. 11 May 2023
Shares in Novavax, a US company advancing protein-based vaccines with its Matrix-M adjuvant, have increased by more than a quarter so far this week. 11 May 2023
The recent European Commission approval for Sotyktu (deucravacitinib), US pharma major Bristol Myers Squibb’s first-in-class, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor for adults with moderate-to-severe plaque psoriasis (PsO), has elicited comment from a leading data and analytics firm. 11 May 2023
French drugmaker Servier has secured European approval for Tibsovo (ivosidenib) in two indications, making it the first and only IDH1 blocker to be available in the region. 11 May 2023
Japan’s largest drugmaker Takeda has announced strong financial results for fiscal year 2022 (period ended March 31, 2023), delivering or exceeding management guidance, driven by the performance of its Growth & Launch Products. 11 May 2023
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
Israel-based Teva Pharmaceutical Industries today announced that the US Food and Drug Administration (FDA) has accepted, and the European Medicines Agency (EMA) has validated, applications for TVB-009P, a biosimilar candidate to Prolia (denosumab). 8 October 2024
UK-based Mestag Therapeutics has entered into a license and collaboration agreement with Merck & Co to explore new therapeutic options for inflammatory diseases. 8 October 2024
With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s Ebglyss (lebrikizumab) adds a new competitor to the atopic dermatitis (AD) market. 8 October 2024
US antivirals specialist Gilead Sciences has released additional data from its pivotal Phase III PURPOSE 2 trial providing an overview of the efficacy and safety of twice-yearly lenacapavir. 8 October 2024
Germany’s Eckert & Ziegler, a specialist in radioisotopes for medical, scientific and industrial applications, has announced a global clinical supply agreement with GlyTherix, an Australian targeted radiotherapy firm specializing in developing antibody radiopharmaceuticals for solid tumors. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Novo Nordisk has reached a settlement with Mylan Pharmaceuticals, now part of Viatris, putting an end to a US patent lawsuit over blockbuster diabetes treatment Ozempic (semaglutide). 8 October 2024
UK-based ViiV Healthcare, the specialist HIV company majority-owned by GSK (LSE: GSK), with Pfizer and Shionogi as shareholders, has announced a milestone in its efforts to achieve widespread international access to its therapies. 7 October 2024
Texas Attorney General Ken Paxton has filed a lawsuit against major pharmaceutical companies, including Eli Lilly (NYSE: LLY), alleging a conspiracy to artificially inflate the prices of insulin by up to 1,000%. 7 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Orchard Therapeutics has signed an exclusive distribution agreement with Turkish drugmaker Er-Kim, for the gene therapy Libmeldy (atidarsagene autotemcel). 7 October 2024
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A. 7 October 2024